NCT02405793撤回2 期
A Phase 2b, Multicenter, Randomized, Single Blind, Fixed Dose, Parallel Group Study to Evaluate the Efficacy and Safety of Meloxicam SoluMatrix® [Test] Capsules and Meloxicam Tablets in Patients With Pain Due to Osteoarthritis of the Knee or Hip
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of a low dose and a high dose of Meloxicam SoluMatrix® Capsules versus Meloxicam Tablets for the treatment of pain due to osteoarthritis of the knee or hip.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary diagnosis of Functional Class I-III osteoarthritis (OA) of the hip or knee
- •Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain
- •Discontinued all analgesic therapy at Screening
- •For women of childbearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control
- •Ability to ambulate
排除标准
- •History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDs, including meloxicam
- •Requires regular (more than 2 doses per week) use of opioid or opioid combination products to control OA pain of the knee or hip
- •Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease
- •Significant difficulties swallowing capsules/tablets or unable to tolerate oral medication
- •Previous participation in another clinical study of Meloxicam Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening
研究组 & 干预措施
Meloxicam low dose test capsule
Experimental
Meloxicam SoluMatrix Capsules - low dose QD
干预措施: Meloxicam Test Capsules (Drug)
Meloxicam high dose test capsule
Experimental
Meloxicam SoluMatrix Capsules - high dose QD
干预措施: Meloxicam Test Capsules (Drug)
Meloxicam tablets
Active Comparator
Meloxicam Tablets QD
干预措施: Meloxicam Tablets (Drug)
结局指标
主要结局
Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.
时间窗: Baseline to Week 6
次要结局
- Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Symptoms Measured Using the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.(Baseline to Week 6)
- Amount of Rescue Medication Taken by Each Subject(Baseline to Week 6/Early Termination)
- Cumulative Discontinuations Due to Lack of Efficacy at Week 6(Baseline to Week 6)
- Responders with at Least a 10-mm Improvement in Mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 6.(Baseline to Week 6)
- Change From Pre-dose to 2 Hours Post-dose in Morning Stiffness Severity as Measured by the Numerical Rating Scale on Day 3.(2 hours after dosing on Day 3)
- Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Function Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score.(Baseline to Week 6)
- Change From Pre-dose to 2 Hours Post-dose in Pain Intensity as Measured by the Numerical Pain Rating Scale on Day 3.(2 hours after dosing on Day 3)
- Change From Pre-dose to 2 Hours Post-dose in Pain Intensity as Measured by the Numerical Pain Rating Scale on Day 14.(2 hours after dosing on Day 14)
- Patient Global Impression of Change(Baseline to Week 6/Early Termination)
- Clinical Global Impression of Change(Baseline to Week 6/Early Termination)
- Safety of Meloxicam SoluMatrix Capsules low dose, Meloxicam SoluMatrix Capsules high dose, and Meloxicam Tablets as Assessed by the Incidence of Adverse Events From Baseline to Week 6 or Early Termination(Baseline to Week 6/Early Termination)
- Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Stiffness Measured Using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score.(Baseline to Week 6)
- Change From Pre-dose to 2 Hours Post-dose in Morning Stiffness Severity as Measured by the Numerical Rating Scale on Day 14.(2 hours after dosing on Day 14)
研究者
相似试验
已完成
2 期
Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory DysfunctionAnovulationNCT00213148EMD Serono271
已完成
2 期
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus AreasZika VirusNCT04917861ModernaTX, Inc.808
已完成
2 期
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney StonesSecondary HyperoxaluriaNephrolithiasisKidney StonesHyperoxaluriaDietary HyperoxaluriaNCT02503345Allena Pharmaceuticals32
已完成
2 期
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)MigraineNCT01613248Allergan834
已完成
2 期
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Chronic Lymphocytic LeukemiaNCT00963105Celgene104